ICON Public Limited Company ICLR

ICLR Company Overview

ICON Public Limited Company is a global clinical research organization (CRO) that provides outsourced drug and medical device development, clinical trial management, consulting, and commercialization services to pharmaceutical, biotechnology, medical device, and government organizations. The company operates within the healthcare services and life sciences industries, with a primary focus on supporting clinical development programs across all phases of drug development. ICON’s core revenue drivers include clinical trial services, laboratory services, decentralized trial technologies, data management, regulatory consulting, and commercialization support for biopharmaceutical clients.

Founded in Ireland in 1990, ICON expanded from a regional CRO into one of the world’s largest contract research providers through organic growth and acquisitions. A major milestone in the company’s evolution was the acquisition of PRA Health Sciences in 2021, which significantly increased ICON’s scale, therapeutic expertise, and global operational footprint. The company’s positioning is supported by long-term relationships with large pharmaceutical companies, broad therapeutic capabilities, integrated technology platforms, and extensive global trial infrastructure.